Abstract
Plasmid DNA is being used as a pharmaceutical agent in vaccination, as well as a basic substance and starting material in gene and cell therapy, and viral vector production. Since the uncontrolled expression of backbone sequences present in such plasmids and the dissemination of antibiotic resistance genes may have profound detrimental effects, an important goal in vector development was to produce supercoiled DNA lacking bacterial backbone sequences: Minicircle (MC) DNA. The Sleeping Beauty (SB) transposon system is a non-viral gene delivery platform enabling a close-to-random profile of genomic integration. In combination, the MC platform greatly enhances SB transposition and transgene integration resulting in higher numbers of stably modified target cells. We have recently developed a strategy for MC-based SB transposition of chimeric antigen receptor (CAR) transgenes that enable improved transposition rates compared to conventional plasmids and rapid manufacturing of therapeutic CAR T cell doses (Monjezi et al. 2016). This advance enables manufacturing CAR T cells in a virus-free process that relies on SB-mediated transposition from MC DNA to accomplish gene-transfer. Advantages of this approach include a strong safety profile due to the nature of the MC itself and the genomic insertion pattern of MC-derived CAR transposons. In addition, stable transposition and high-level CAR transgene expression, as well as easy and reproducible handling, make MCs a preferred vector source for gene-transfer in advanced cellular and gene therapy. In this chapter, we will review our experience in MC-based CAR T cell engineering and discuss our recent advances in MC manufacturing to accelerate both pre-clinical and clinical implementation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aronovich EL, McIvor RS, Hackett PB (2011) The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 20(R1):R14–R20
Beatty GL, Haas AR, Maus MV et al (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2(2):112–120
Bigger BW, Tolmachov O, Collomber JM, Fragkos M, Palaszewski I, Coutelle C (2001) An araC-controlled bacterial cre expression system to produce DNA MC vectors for nuclear and mitochondrial gene therapy. J Biol Chem 276:23018–23027
Brentjens RJ, Riviere I, Park JH et al (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18):4817–4828
Brown CE, Wright CL, Naranjo A et al (2005) Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 297(1–2):39–52
Chabot S, Orio J et al (2013) Minicircle DNA Electrotransfer for efficient Tissue targeted Gene Delivery. Gene Ther 20(1):62–68
Chen ZY, He CY, Ehrhardt A, Kay MA (2003) MC DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8:495–500
Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J (1997) A new DNA vehicle for nonviral gene delivery: supercoiled MC. Gene Ther 4:1341–1349
Davila ML, Riviere I, Wang X et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 6(224):224–225
Di Stasi A, Tey SK, Dotti G et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673–1683
Eberl L, Kristensen CS, Givskov M, Grohmann E, Gerlitz M, Schwab H (1994) Analysis of the multimer resolution system encoded by the parCBA operon of broad-host-range plasmid RP4. Mol Microbiol 12:131–141
Field AC, Vink C, Gabriel R et al (2013) Comparison of lentiviral and sleeping beauty mediated alphabeta T cell receptor gene-transfer. PLoS ONE 8(6):e68201
Gossen JA, de Leeuw WJF, Molijn AC et al (1993) Plasmid rescue from transgenic mouse DNA using lacI repressor protein conjugated to magnetic beads. Biotechniques 14:624–629
Huang X, Guo H, Kang J et al (2008) Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 16(3):580–589
Hudecek M, Lupo-Stanghellini MT, Kosasih PL et al (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19(12):3153–3164
Hudecek M, Sommermeyer D, Kosasih PL et al (2015) The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 3(2):125–135
Ivics Z, Hackett PB, Plasterk RH, Izsvak Z (1997) Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91(4):501–510
Izsvak Z, Hackett PB, Cooper LJ, Ivics Z (2010) Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. BioEssays 32(9):756–767
Ivics Z, Izsvak Z (2011) Nonviral gene delivery with the sleeping beauty transposon system. Hum Gene Ther 22(9):1043–1051
Jechlinger W, Azimpour Tabrizi T, Lubitz W, Mayrhofer P (2004) MC DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J Mol Microbiol Biotechnol 8:222–231
Jin Z, Maiti S, Huls H et al (2011) The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 18(9):849–856
Kolbelt D, Schleef M, Schmeer M, Aumann J, Schlag PM, Walther W (2013) Performance of high quality minicircle DNA for in vitro and in vivo gene-transfer. Mol Biotechnol 53(1):80–89
Mates L, Chuah MK, Belay E et al (2009) Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene-transfer in vertebrates. Nat Genet 41(6):753–761
Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507–1517
Mayrhofer P, Blaesen M, Schleef M, Jechlinger W (2008) Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med 10(11):1253–1269
Monjezi R, Miskey C, Gogishvili T et al (2016) Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia. doi:10.1038/leu.2016.180 (epub ahead of print)
Nehlsen K, Broll S, Bode J (2006) Replicating MCs: generation of nonviral episomes for the efficient modification of dividing cells. Gene Ther Mol Biol 10:233–244
Peng PD, Cohen CJ, Yang S et al (2009) Efficient nonviral Sleeping Beauty transposon-based TCR gene-transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther 16(8):1042–1049
Ramos CA, Savoldo B, Dotti G (2014) CD19-CAR trials. Cancer J 20(2):112–118
Sadelain M, Papapetrou EP, Bushman FD (2011) Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 12(1):51–58
Schleef M, Schmeer M (2011) Minicircle—Die nächste Generation nicht-viraler Gentherapie-Vektoren. Parm unserer Zeit 3:220–224
Schleef M (ed) (2013) MC and Miniplasmid DNA vectors—the future of non-viral and viral gene-transfer. Wiley-Blackwell, Weinheim
Schleef M, Schirmbeck R, Reiser M, Michel M-L, Schmeer M (2015) MC: next generation DNA vectors for vaccination. In: Walther W, Stein U (eds) Gene therapy of solid cancers: methods and protocols (Methods in Molecular Biology) vol 1317. Springer, New York
Schmeer M, Schleef M (2014) Pharmaceutical grade large-scale plasmid DNA manufacturing process. In: Rinaldi M et al (eds) Methods in molecular biology, DNA Vaccines, vol 1143, pp 219–240. Springer, Heidelberg
Singh H, Manuri PR, Olivares S et al (2008) Redirecting specificity of T cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68(8):2961–2971
Singh H, Figliola MJ, Dawson MJ et al (2013) Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE 8(5):e64138
Singh H, Huls H, Kebriaei P, Cooper LJ (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257(1):181–190
Smith MC, Thorpe HM (2002) Diversity in the serine recombinases. Mol Microbiol 44:299–307
Sommermeyer D, Hudecek M, Kosasih PL et al (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30(2):492–500
Swierczek M, Izsvak Z, Ivics Z (2012) The Sleeping Beauty transposon system for clinical applications. Expert Opin Biol Ther 12(2):139–153
Thomson JG, Ow DW (2006) Site-specific recombination systems for the genetic manipulation of eukaryotic genomes. Genesis 44:465–476
Turtle CJ, Hudecek M, Jensen MC, Riddell SR (2012) Engineered T cells for anti-cancer therapy. Curr Opin Immunol 24(5):633–639
Turtle CJ, Hanafi LA, Berger C et al (2016) CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J Clin Invest. 126(6):2123–2138
Wang X, Chang WC, Wong CW et al (2011) A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118(5):1255–1263
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hudecek, M. et al. (2016). Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells. In: Walther, W. (eds) Current Strategies in Cancer Gene Therapy. Recent Results in Cancer Research, vol 209. Springer, Cham. https://doi.org/10.1007/978-3-319-42934-2_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-42934-2_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42932-8
Online ISBN: 978-3-319-42934-2
eBook Packages: MedicineMedicine (R0)